公开(公告)号：US20190119200A1

公开(公告)日：2019-04-25

申请号：US16091919

申请日：2017-04-06

申请人： AbbVie Inc.

发明人： Lawrence A. Black ,  William H. Bunnelle ,  Da Chen ,  Bruce Clapham ,  David A. Degoey ,  Xiangjun Deng ,  Liqiang Fu ,  Lisa A. Hazelwood ,  Linglong Kong ,  Qingyu Lang ,  Chih-Hung Lee ,  Mingfeng Li ,  Greta L. Lundgaard ,  Meena V. Patel ,  Ruihong Tao ,  Lin Zhang ,  Qingwei Zhang ,  Qiangang Zheng ,  Wei Zhu

IPC分类号： C07C235/34 ,  C07D213/69 ,  C07D321/10 ,  C07D307/86 ,  C07D317/46 ,  C07D333/24 ,  C07C323/52 ,  C07F9/38 ,  C07C313/04 ,  C07D209/20 ,  C07C311/32 ,  C07D305/06 ,  C07D213/71 ,  C07C311/51 ,  C07D239/72 ,  C07D239/52 ,  C07D257/06 ,  C07D215/50 ,  C07D217/26 ,  C07D498/04 ,  C07D307/33

摘要： Compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein G1, G2, G3, L1, L2, and L3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by the modulation of lysophosphatidic acid receptor 1. Methods for making the compounds are described. Also described are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.